Key result
Thrombolysis prevents hemodynamic collapse in intermediate-risk pulmonary embolism but increases the risk of major bleeding, particularly in patients over 75 years of age.
Why the study?
Does thrombolysis prevent hemodynamic collapse in patients with massive and submassive pulmonary embolism?
Does thrombolysis prevent hemodynamic collapse in patients with massive and submassive pulmonary embolism?
Thrombolysis is the treatment of choice for high-risk PE and should be considered in high-intermediate risk PE patients ≤75 years with low bleeding risk, while reduced dose or catheter-based therapies show promise.
Answers are grounded in this paper and cite their sources.
May warrant caution with thrombolysis in intermediate-risk PE patients >75 years; leaves open optimal dosing and catheter-based alternatives.
PURPOSE OF REVIEW: Although early pulmonary revascularization is the treatment of choice for patients with high-risk (massive) pulmonary embolism, it remains controversial in patients with intermediate-risk (submassive) pulmonary embolism until recently. Recent published data on the management of high-risk and intermediate-risk pulmonary embolism patients will be the main focus of this review. RECENT FINDINGS: The PEITHO trial supports the rationale of risk stratification in normotensive patients with pulmonary embolism. Patients with right ventricular dilation on echocardiography and positive cardiac troponin test have a high intermediate risk of complication and death. Thrombolysis prevents hemodynamic collapse in these patients but with an increased risk of major bleeding particularly in older patients (>75 years). Reduced dose of thrombolysis and catheter-based reperfusion with or without fibrinolysis have shown promising results. SUMMARY: Thrombolysis is the treatment of choice for patients with high-risk pulmonary embolism. Surgical embolectomy is recommended in case of absolute contra-indication to thrombolysis. In patients with acute right ventricular dysfunction on cardiac imaging and myocardial injury, thrombolysis should be considered if they are 75 years or less of age and are at low risk of bleeding. Full-dose thrombolysis may be excessively risky in patients over 75 years. In patients with either RV dilation or elevated cardiac biomarker, thrombolysis is not recommended.
No takes yet. Share an insight, caveat, or question.
Sanchez et al. (2014) conducted a review in massive and submassive pulmonary embolism. Thrombolysis was evaluated. Thrombolysis prevents hemodynamic collapse in intermediate-risk pulmonary embolism but increases the risk of major bleeding, particularly in patients over 75 years of age.
Synapse has enriched 10 related papers. Consider them for comparative context: